Drugs / Sodium Risedronate Hydrate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00447915 Comparator | Mar 2007 → Aug 2011 | osteoporosis | Chugai Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Risedronate Hydrate | “Comparative Study With Sodium Risedronate Hydrate(RIS) With Vertebral Fracture as an Index” NCT00447915 ↗ |
| Known as | RIS | “Comparative Study With Sodium Risedronate Hydrate(RIS) With Vertebral Fracture as an Index” NCT00447915 ↗ |
| Route | Oral | “2.5 mg(p.o.)/day for 36 months” NCT00447915 ↗ |